Citigroup Inc Alpha Tau Medical Ltd. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$2.98 - $4.24 $961,923 - $1.37 Million	-322,793 Reduced 95.57%	14,968 $56,000
Q2 2023 Aug 10, 2023	BUY	$2.76 - $4.72 $865,693 - $1.48 Million	313,657 Added 1301.27%	337,761 $1.48 Million
Q1 2023 May 11, 2023	SELL	$2.78 - $4.83 $61 - $106	-22 Reduced 0.09%	24,104 $69,000
Q4 2022 Feb 09, 2023	SELL	$3.05 - $5.49 $17,055 - $30,700	-5,592 Reduced 18.82%	24,126 $76,000
Q3 2022 Nov 10, 2022	BUY	$0.65 - $11.0 $19,316 - $326,898	29,718 New	29,718 $174,000
Q2 2022 Aug 10, 2022	SELL	$5.19 - $12.67 $2,387 - $5,828	-460 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$8.92 - $15.3 $4,103 - $7,038	460 New	460 $5,000

1.35M

Ticker DRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,011,296
Market Cap $270M
Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast canc...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.